New Investments, Acquisitions Fostering Growth - Research Report on Teleflex Incorporated, C.R. Bard, Inc., CareFusion Corporation, Wright Medical Group, Inc. and NuVasive, Inc.

NEW YORK, March 1, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Teleflex Incorporated (NYSE: TFX), C.R. Bard, Inc. (NYSE: BCR), CareFusion Corporation (NYSE: CFN) (NYSE: CFN), Wright Medical Group, Inc. (NASDAQ: WMGI) and NuVasive, Inc. (NASDAQ: NUVA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Teleflex Incorporated Research Report

Teleflex recently reported that its fourth quarter revenue rose 4 percent to $419 million. Teleflex CEO Benson Smith comments that the LMA International N.V. acquisition greatly contributed to earnings growth. He also said that the company was able to expand margins and through higher sales volume, new product introductions and improved pricing. For the coming year, the company's goals include improving its operating platform, gaining additional market share, and generating revenue above industry average Teleflex expects to do this by investing in innovative technologies and prudently investing capital. Morgan Stanley reiterated its Overweight rating on the company and noted, "Several underappreciated factors from the quarter leave us more comfortable with our recent upgrade." The Full Research Report on Teleflex Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/c7f9_TFX]

--

C.R. Bard, Inc. Research Report

CR Bard delivered strong fourth quarter results, with diluted EPS of $1.52 and $1.70 on adjusted basis. The company's results exceeded guidance by a couple of cents. Many are expecting CR Bard to win a vascular graft intellectual property dispute against privately held Gore soon, and the effects of this may be reflected as early as the first quarter of 2013. Furthermore, CR Bard's acquisition of Neomend, a privately owned innovative surgical sealants maker, may also brighten the company's prospects. To accelerate growth, the company is presently investing in emerging markets and new product categories. The Full Research Report on C.R. Bard, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/1101_BCR]

--

CareFusion Corporation (NYSE: CFN) Research Report

CareFusion Corporation reported that its second quarter fiscal 2013 revenue increased 2 percent to $909 million, driven by the company's strong Procedural Solutions segment. It highlighted good performance from its infection prevention and medical specialties units, which delivered the highest revenue growth in more than two years. Over the first half of fiscal 2013, the company expanded operating margins, invested in innovation and new markets. The company's expansion outside the United States through its acquisition of Intermed may also help further accelerate growth. The Full Research Report on CareFusion Corporation (NYSE: CFN) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/03a4_CFN]

--

Wright Medical Group, Inc. Research Report

Wright Medical Group has impressed many analysts and investors with its fourth quarter and full year results. For 2012, the company was able to implement transformational changes like leveraging its direct sales organization, introducing new products, driving productivity gains and increasing its medical education programs. These changes are reflected in the growth of its foot and ankle business. Following its results, Leerink Swann upgraded the company from "market perform" to "outperform." Analysts at Wunderlich also raised their price target on the shares of Wright Medical. Its recent merger with BioMetric Therapeutics further brightens the company's outlook, accelerating growth in Wright's extremities business. With The Full Research Report on Wright Medical Group, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/78f1_WMGI]

--

NuVasive, Inc. Research Report

NuVasive closed 2012 with strong results, reporting 15 percent growth in revenue for the full year. Moving forward, the company is excited about its growing clinical evidence business, new products and expansion to international markets. NuVasive's most recent expansion move is offering eXTreme Lateral Interbody Fusion (XLIF) in Japan. The company is eager to further introduce the product in Japan and drive the shift toward minimally invasive approaches in the world's second largest spine market. Its long-term plans include evolving into a $1 billion company with steadily increasing profitability. By accelerating its speed of innovation and expanding to lucrative markets, NuVasive may be on track towards this goal. The Full Research Report on NuVasive, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/463c_NUVA]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.

Contact: Patricia Byers
Email: press@Investors-Alliance.com
Main: +1-480-745-7826

SOURCE Investors-Alliance